Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct;205(4):1404-1410.
doi: 10.1111/bjh.19617. Epub 2024 Jun 28.

Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi

Federica Cavallo  1   2 , Michele Clerico  1 , Elisa Lucchini  3 , Anna Castiglione  4 , Alessandro Re  5 , Vittorio Ruggiero Zilioli  6 , Carlo Visco  7 , Monica Tani  8 , Jacopo Olivieri  9 , Luca Arcaini  10   11 , Alberto Fabbri  12 , Gianluca Gaidano  13 , Anna Dodero  14 , Francesco Zaja  3   15
Affiliations
Clinical Trial

Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi

Federica Cavallo et al. Br J Haematol. 2024 Oct.

Abstract

Mantle cell lymphoma (MCL) is a rare lymphoproliferative neoplasm considered incurable, with a median survival of 3-5 years. In recent years, Bruton's tyrosine kinase inhibitors (BTKi) have been introduced, demonstrating high therapeutic activity. However, the prognosis for MCL patients failing ibrutinib therapy is particularly poor, with a survival expectation of a few months. In this phase II trial, we assessed the efficacy and safety of the carfilzomib-lenalidomide-dexamethasone (KRD) combination in MCL patients who were relapsed/refractory (R/R) or intolerant to BTKi and in need of treatment. The primary objective of the study was to evaluate the antitumor efficacy of the KRD combination in terms of 12-month overall survival (12-month OS). From September 2019 to December 2020, 16 patients were enrolled from 11 Italian centers. After a median follow-up of 2.37 months (95% CI 0.92-6.47), the 12-month OS was 13%. The rate of grade 3-4 adverse events (AEs) was 35%, and the overall response rate (ORR) was 19%. These results led to the premature termination of enrollment, as defined in the protocol stopping rules. The efficacy of the KRD combination in advanced-stage MCL patients who are R/R to BTKi is unsatisfactory and too toxic.

Keywords: carfilzomib; clinical haematology; lenalidomide; mantle cell lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Armitage JO, Weisenburger DD. New approach to classifying non‐Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non‐Hodgkin's lymphoma classification project. J Clin Oncol. 1998;16(8):2780–2795.
    1. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142(2):149–165. https://doi.org/10.1111/j.1365‐2141.2008.07124.x
    1. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89(6):2067–2078.
    1. Velders GA, Kluin‐Nelemans JC, De Boer C, Hermans J, Noordijk EM, Schuuring E, et al. Mantle‐cell lymphoma: a population‐based clinical study. J Clin Oncol. 1996;14(4):1269–1274. https://doi.org/10.1200/JCO.1996.14.4.1269
    1. Andersen NS, Jensen MK, de Nully BP, Geisler CH. A Danish population‐based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer. 2002;38(3):401–408.

Publication types

MeSH terms

LinkOut - more resources